RCT: CV outcomes with semaglutide in people with obesity but no T2D
In this medfyle
Semaglutide, a GLP-1RA, has been shown to reduce the risk of adverse CV events in people with overweight and diabetes. The SELECT study was performed to assess whether semaglutide can also reduce CV risk in people with overweight or obesity, but with no history of diabetes.
This Medfyle was published more than two years ago. More recent Medfyle on this topic may now be available.
About this Medfyle
©2024 Medfyle. All rights reserved.
Original article:
Lincoff AM, Brown-Frandsen K, Colhoun HM, Deanfield J, Emerson SS, Esbjerg S, Hardt-Lindberg S, Hovingh GK, Kahn SE, Kushner RF, Lingvay I, Oral TK, Michelsen MM, Plutzky J, Tornøe CW, Ryan DH; SELECT Trial Investigators. Semaglutide and Cardiovascular Outcomes in Obesity without Diabetes. N Engl J Med. 2023 Dec 14;389(24):2221-2232. doi: 10.1056/NEJMoa2307563. Epub 2023 Nov 11. PMID: 37952131.
The summary content was prepared by Marie Farrow for Medfyle, reviewed by Marco Comoglio, MD.
The authors of the original article and the publisher had no part in the creation of the summary.
